Drug Profile
t2c 001
Alternative Names: Autologous bone marrow-derived mononuclear cell fraction; t2c001; t2c001-AMI; t2c001-CHD; t2c001-DCM; t2c001-SWLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator t2cure
- Class Heart failure therapies; Ischaemic heart disorder therapies; Stem cell therapies
- Mechanism of Action Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiomyopathies; Heart failure; Ischaemic heart disorders; Myocardial infarction; Thromboangiitis obliterans
Most Recent Events
- 28 Jul 2015 No recent reports on development identified - Phase-I/II for Cardiomyopathy, Heart failure, Ischaemic heart disorders and Thromboangiitis obliterans in Germany (Intra-arterial)
- 28 Jul 2015 No recent reports on development identified - Phase-II for Myocardial infarction in Germany (Intra-arterial)
- 20 Sep 2010 t2c 001 receives Orphan Drug status for Thromboangiitis obliterans in European Union